Revenues (Tables)

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue by Product and by Geographic Area

Revenues were as follows (in millions):

	Year ended December 31, 2023						Year ended December 31, 2022						Year ended December 31, 2021
	U.S.		ROW		Total		U.S.		ROW		Total		U.S.		ROW		Total
Prolia	$	2,733	$	1,315	$	4,048	$	2,465	$	1,163	$	3,628	$	2,150	$	1,098	$	3,248
ENBREL	3,650		47		3,697		4,044		73		4,117		4,352		113		4,465
Otezla	1,777		411		2,188		1,886		402		2,288		1,804		445		2,249
XGEVA	1,527		585		2,112		1,480		534		2,014		1,434		584		2,018
Repatha	793		842		1,635		608		688		1,296		557		560		1,117
Nplate	996		481		1,477		848		459		1,307		566		461		1,027
KYPROLIS	921		482		1,403		850		397		1,247		736		372		1,108
Aranesp	452		910		1,362		521		900		1,421		537		943		1,480
EVENITY	809		351		1,160		533		254		787		331		199		530
Vectibix	461		523		984		396		497		893		347		526		873
BLINCYTO	566		295		861		336		247		583		278		194		472
TEPEZZA(1)	441		7		448		—		—		—		—		—		—
KRYSTEXXA(1)	272		—		272		—		—		—		—		—		—
Other products(2)	3,874		1,389		5,263		3,776		1,444		5,220		4,194		1,516		5,710
Total product sales(3)	19,272		7,638		26,910		17,743		7,058		24,801		17,286		7,011		24,297
Other revenues	534		746		1,280		852		670		1,522		908		774		1,682
Total revenues	$	19,806	$	8,384	$	28,190	$	18,595	$	7,728	$	26,323	$	18,194	$	7,785	$	25,979

____________

(1)    TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on October 6, 2023, and includes product sales from the acquisition date through December 31, 2023.

(2)    Consists of product sales of our non-principal products, as well as sales prior to the divestiture of our Bergamo and Gensenta subsidiaries in the second quarter of 2023 and fourth quarter of 2022, respectively.

(3)    Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2023, 2022 and 2021.

Revenues Earned from Major Customers

For the year ended December 31, 2023, on a combined basis, these customers accounted for 79% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):

	Years ended December 31,
	2023			2022			2021
McKesson Corporation:
Gross product sales	$	19,035		$	17,305		$	15,187
% of total gross revenues	33		%	35		%	33		%
Cencora, Inc. (formerly AmerisourceBergen Corporation):
Gross product sales	$	16,625		$	15,443		$	14,783
% of total gross revenues	29		%	31		%	32		%
Cardinal Health, Inc.:
Gross product sales	$	9,775		$	8,319		$	7,681
% of total gross revenues	17		%	16		%	17		%